Latest News

Pertrum Tablet combines two analgesics ; Tramadol and Paracetamol which is highly effective than monotherapy. Tramadol a centrally acting analgesic with a unique dual mechanism of action: Tramadol works for pain management by binding with μ-opioid receptors in the CNS, essentially blocking pain signals from reaching the brain, and also by inhibiting the reuptake of neurotransmitters like Serotonin and Norepinephrine which further contributes to pain relief. Paracetamol is a non-opiate, non-salicylate analgesic. Paracetamol blocks the production prostaglandin synthesis in the body that are responsible for pain and fever. The analgesic of choice for mild to moderate pain and to reduce fever. Peratrum Tablet a more potent analgesic than oral NSAIDs.

Finotab tablet is a preparation of Finerenone. It is a novel non-steroidal selective & highly potent mineralocorticoid receptor antagonist.Finerenone has been recently approved by the US Food and Drug Administration for the treatment of reducing the risk of sustained eGFR decline, end stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D). FINOTAB: A Novel Therapy for Cardio-Renal Protection, taking once daily blocks MR mediated sodium reabsorption and MR over activation in both epithelial (e.g., kidney) and nonepithelial (e.g., heart, and blood vessels) tissues. As a result, it helps to reduce the progression of chronic kidney disease (CKD) and cardiovascular (CV) risks. FINOTAB is a safe and effective option without sexual side effects and less chance of hyperkalemia. It is available as 10 mg tablet. It is launched on July 14, 2025.

Colagen Plus is a Combination of Glucosamine HCl 150 mg, Chondroitin Sulfate 120 mg, and Undenatured Type-II Collagen 40 mg. Indicated for Osteoarthritis, Rheumatoid arthritis, Joint pain & inflammation. Each pack contains 30’s Alu Alu blister packs. It was Launched on July 30, 2025.